Curriculum Vitae Dr Clare Louise Hague

CURRENT APPOINTMENTS Aug 2016-present Senior Director, Global Pricing & Market Access

Global Lead for Health Economics & Outcomes Research including HTA Statistics for the Haematology/Oncology Franchise

Celgene Management Sàrl, Boudry, Switzerland

Global Lead for HEOR, Haematology / Oncology, also overseeing HTA statistics Jan 2015-Present University Lecturer & Academic Supervisor

Department of Health Sciences and Health Policy Faculty of Humanities & Social Sciences University of Lucerne, Switzerland

PREVIOUS APPOINTMENTS Sept 2015-July 2016 Head of Health Economics & Outcomes Research Haematology / Oncology Medical Affairs (EMEA)

Celgene R&D Sàrl, Boudry Switzerland

Member of Medical Affairs Leadership Team

HEOR Skills lead for the Medical Affairs organization

EFPIA Company lead for WP6 (Policy Makers, HTA Agencies, Payers, Patients) for a pan EU Real World Evidence Innovative Medicines Initiative (HARMONY) in Hematological Malignancies. This five-year project has a total budget of E 40 million.

Sept 2015-July 2016 Interim Head of Health Economics & Pricing, UK & Ireland

Haematology / Oncology & Immunology / Inflammation Celgene Ltd, Stockley Park, Uxbridge, UK

Interim Head of the Health Economics & Pricing Team for the UK with line management responsibility for the HEOR & Pricing team and for securing reimbursement of Celgene’s products across haematology/oncology and immunology & inflammation.

Key achievements:

Working with the UK HEOR Team, secured reimbursement of 3 assets from NICE o Otezla (Apremilast) for psoriatic arthritis o http://ir.celgene.com/releasedetail.cfm?releaseid=1005287 o Otzela (Apremilast) for moderate to severe plaque psoriasis

https://www.nice.org.uk/guidance/TA419/chapter/1-Recommendations o IMNOVID® in combination with dexamethasone for adults at third or subsequent

relapse following three previous treatments including both REVLIMID® (lenalidomide) and bortezomib. https://www.nice.org.uk/news/article/nice-reviews-multiple-myeloma-drug-and-approves-for-routine-use

2

April 2014-Aug 2015 Head of Health Technology Assessment, EU+ Canada Biogen International, Zug, Switzerland

Deputized for the VP Market Access (EU+ Canada)

Line management responsibility for EU+ Canada Market Access Team (9 direct reports)

Secretary & Member of the EU+ Canada Market Access Leadership Team

Biogen Company Representative on the following External Forums

EuropaBio HTA Task Force BioIndustry Association (BIA) informing NICE’s Methods of Technology Appraisal

HTA Working Group on the OMP Task Force Noteworthy Achievements

1 Biogen Award for Living the Values; 2 Biogen Awards for Teaming & Leading; 3 Biogen Awards for Achieving Excellence

Sept 2013-March 2014 Director & Head of Health Economics (EMEA) Commercial Operations Onyx Pharmaceuticals International GmBH, Zug, Switzerland *Acquired by Amgen on Aug 26, 2013

Head of Health Economics for Europe & MEA:

Developed and executed the EU evidence generation plan for Carfilzomib in multiple myeloma in EMEA

Project managed pricing research

Developed, designed, conducted, analyzed and reported HEOR activities

Collaborated with interdisciplinary teams to review and provide EU HEOR input for early phase II &III and late phase IIIb/IV clinical trials and life cycle management.

Aug 2011-Aug 2013 Global Payer Evidence Director, Oncology iMED AstraZeneca, Alderley Park, Cheshire, UK

Global Payer Evidence Lead for the Emerging Oncology / Haem Onc Portfolio: Scientific Responsibilities

Scientific Referee to the National Institute for Health Research (NIHR) Health Technology Assessment Programme.

Scientific Reviewer for the National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre.

Scientific Referee for the UK HTA Commissioning Board on Clinical Trials. Noteworthy Achievements

2013 CEO Award for Exceptional Delivery in the area of Scientific Leadership. Sept 2005-August 2013 Honorary Fellow Health Economics & Decision Science,

ScHARR, University of Sheffield, UK

3

Sept 2008-July 2011 Global Value Demonstration Leader, Oncology AstraZeneca, Alderley Park, Cheshire, UK

Director level responsibilities included: o Leader of cross-functional Strategic Payer Team for assets in acute myeloid

leukaemia and ovarian & breast cancer. o Provided input into the global clinical trials (relevant clinical/ economic endpoints,

PRO strategies etc) & developed global payer evidence strategies. o Conducted value-based pricing analyses to inform pricing decisions. o Liaised with key affiliates to validate global payer strategies and evidence

generation plans. o Led an early payer scientific advice interaction with NICE on an ovarian cancer

asset (olaparib). Noteworthy Achievements

Distinguished performance rating Aug 2007-Aug 2008 Global Senior Health Economics & Outcomes Research

Scientist, Oncology AstraZeneca, Alderley Park, Cheshire, UK

Led health economic activities on olaparib for breast and ovarian cancer (phase II asset), saracatinib for ovarian cancer (phase 2 asset) and selumetinib for melanoma (phase II asset)

Sept 2005-July 2007 Senior Health Economist RTI-Health Solutions - Europe, Manchester Science Park Led successful National reimbursement submissions in oncology:

Developed Reimbursement Submissions to NICE and SMC for new treatments for NSCLC & metastatic breast cancer on behalf of Eli Lilly.

o Lobbied with NICE to over-turn their decision not to reimburse gemcitabine+paclitaxel for metastatic breast cancer which was successful

Developed & published the US Health Economic Value Story for MedImmune’s FluMist vaccine for influenza in healthy children.

Noteworthy Achievements

Early Career Author Award from the Research Triangle Institute, North Carolina Feb 2002-Aug 2005 MRC Senior Research Fellow

Health Economics & Decision Science School of Health & Related Research, University of Sheffield

Led Critical Care Health Economic Projects and Initiatives in the UK:

Line management responsibility of a dedicated Research team

Principal Investigator of an MRC Funded Multi-centre Study with line management & budget responsibility.

o This study involved prospective clinical and financial data capture from 70 hospitals across the United Kingdom over a 3-month period (7,433 patients).

4

Developed the UK Department of Health’s Healthcare Resource Group Reimbursement System for Adult Critical Care Units using information gathered from the MRC study

Principal Investigator of a NCCHTA Funded Multi-Centre Randomized Controlled Trial & Concurrent Economic evaluation of ECMO for Severe Respiratory Failure, in collaboration with the University of East Anglia, the London School of Hygiene & Tropical Medicine, Glenfield Hospital and the University of Leicester

Scientific Responsibilities:

Journal Reviewer for Intensive Care Medicine

Journal Reviewer for the International Journal for Quality in Health Care

Journal Reviewer for Pharmacoeconomics

Health Economics Reviewer for the Chief Scientific Office of the NHS Executive

Member of the UK Department of Health’s Working Group on Funding

Member of the NHS Information Authority’s Project Board for Critical Care

Member of the ESICM Scientific Advisory Board for the SAPS III: ‘From the Evaluation of the Individual Patient to the Evaluation of the ICU’ Study. European Society of Intensive Care Medicine (ESICM).

Member of the Board of the Faculty of Medicine, University of Sheffield June 1995-Jan 2002 Co-Founder & Director of Research Medical Economics & Research Centre, Sheffield (MERCS) Sheffield Teaching Hospitals NHS Trust

Set up a registered charity & limited company

Hired and led research team

Company secretary responsible for the financial management of the organization

Line management of research & responsibility for business development / income generation

Noteworthy Achievements

Worked as part of a cross-functional team to implement the first patient-level costing system into the adult intensive care unit in Europe

Developed and implemented the Critical Care National Cost Block System (a national expenditure bench marking system) that measured expenditure across 100 critical care units in the UK as part of a National Working Group

Developed & implemented the North Trent Audit Programme

Secretary of the ESICM Working Group on Cost-Effectiveness

Performed health economic consultancy projects for the following companies: o Hill-Rom o AstraZeneca o Novartis Consumer Health o Bayer o Knoll Pharmaceuticals o Hoffmann-La-Roche o B Braun o Draeger o The Liposome Company

5

Sept 1993-July 1994 Assistant Product Manager (Analgesics) Asta Medica S.A., Madrid (Spain)

Implemented marketing strategies to drive national sales of MST Continus® for severe cancer pain.

Assistant Secretary of the Spanish Society of Palliative Care (SECPAL).

QUALIFICATIONS

Aug 2007 PhD. Health Economics & Health Services Research University of Sheffield

Sept 2001-June 2002 MSc. Modules in Health Economics, Operational Research and Methods of Economic Evaluation University of Sheffield

Aug 2000 MSc. Modules in Health Sciences & Clinical Evaluation

(Distinction) University of York June 1995 BA (Hons) International Business & Spanish Sheffield Business School, Sheffield Hallam University

FELLOWSHIPS

March 2001 Awarded a 4-year Medical Research Council (MRC) Special Training Fellowship in Health Services Research

ADDITIONAL ROLES HELD Feb 2006 – Sept 2008 Deputy Chair of the European Society of Intensive Care

Medicine Research Group on Health Economics Oct 2002 – Aug 2005 Member of the Board of the Faculty of Medicine, University of Sheffield Jan 2003-Aug 2005 Member of the Department of Health Working Group on

Critical Care Funding Sept 1997 – Feb 2002 Secretary of the European Society of Intensive Care Medicine

Working Group on Cost Effectiveness

PUBLISHED BIBLIOGRAPHIES

Marquis’ Who’s Who in the World

Marquis’ Who’s Who in America

Marquis’ Who’s Who in Medicine & Health Care

Marquis’ Who’s Who in Science & Engineering

The Cambridge Blue Book

The Dictionary of International Biography

6

PUBLICATIONS

1. Edbrooke DL, Hibbert CL, Jacobs P. Health Economics of Intensive Care. Yearbook on Intensive Care and Emergency Medicine. Series Editor: J. L Vincent. Publishers: Springer-Verlang. March 1999.

2. Edbrooke DL, Hibbert CL. Fungal Infections in the ICU - Disease Management Monograph. Chapter 8 - Pharmacoeconomics of anti-fungal therapy in the ICU. In association with The Liposome Company.

3. Hibbert CL, Edbrooke DL. Economic Outcomes. Outcomes in Critical Care Editors S Ridley and D Young. Publishers Butterworth Heinemann. Published Jan 2002.

4. Edbrooke DL, Stevens VG, Hibbert CL, Mann AJ, Wilson AJ. A new method of accurately identifying costs of individual patients in intensive care: the initial results. Intensive Care Medicine 1997: 23:645-650

5. Edbrooke DL, Stevens VG, Hibbert CL, Kingsley JM, Smith S, Wilson AJ. High dependency units in England - The lack of provision and the cost of addressing the shortfall. Care of the Critically Ill 1997; 13:6:216-218

6. Smith S, Stevens VG, Edbrooke DL, Hibbert CL, Kingsley JM. Impact of the ageing population on intensive care unit provision. Nursing in Critical Care 1997;2:5:239-242.

7. Edbrooke DL, Hibbert CL, Mills GM. Does it make sense to correlate TISS points to ICU costs? Acta Anaesthesiologica Scandinavica 1998;112:42:195-196.

8. Stevens VG, Hibbert CL, Edbrooke DL. Evaluation of proposed case-mix criteria as a basis for costing patients in the adult general Intensive Care Unit. Anaesthesia 1998;53:944-950.

9. Edbrooke DL, Hibbert CL, Ridley S, Long T, Dickie H. The development of a method for comparative costing of individual intensive care units. Intensive Care Working Group on Costs. Anaesthesia 1999;54:110-121.

10. Hibbert CL, Edbrooke DL, Kingsley JM, Corcoran MC, Bright N. Cost considerations for the use of low-air loss bed therapy in the adult intensive care unit. Intensive and Critical Care Nursing 1999;15:3:154-162.

11. Edbrooke DL, Hibbert CL, Chalfin D. Cost determination and economic evaluation in critical care. Educational primer published by the European Society of Intensive Care Medicine. October 1999.

12. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn J. The patient-related costs of sepsis patients in a UK adult general intensive care unit. Critical Care Medicine 1999;27:9:1760-1767.

13. Edbrooke DL, Hibbert CL, Corcoran MC. Costing Methods in Intensive Care. Critical Care Monitor 1999;4:43-47

14. Edbrooke DL, Hibbert CL. Cost-Determination and Economic Evaluation in Critical Care. Current Opinion in Critical Care 1999; 5:316-320

15. Tolley K, Pang F, Brown M, Hibbert C, Beck E. The value of observational datasets in the economic evaluation of pharmaceuticals. Health Economists’ Study Group Paper, Newcastle, Jan 2000

16. Edbrooke DL, Hibbert CL. Cost-effectiveness in Intensive Care. Published by Drager Werke. 17. Hibbert CL. An economic evaluation of enteral feeds in the ICU. For Novartis Consumer

Health (Formulary Pack). Published July 2000. 18. Hibbert CL, Edbrooke DL, Coates E. Cost-effectiveness of immunonutrition in the critically

ill patient. Complete Nutrition 2001;1:1:9-13. 19. Edbrooke DL, Ridley SA, Hibbert CL, Corcoran MC. Variations in expenditure between adult

general intensive care units. Anaesthesia 2001;56:208-216. 20. Jacobs P, Edbrooke DL, Hibbert CL, Fassbender K, Corcoran MC. Descriptive patient data as

an explanation for the variation in average daily costs in intensive care. Anaesthesia 2001;56:643-647.

7

21. Edbrooke DL, Corcoran MC, Dean J, Hibbert CL, Coates EJ, Jacobs P. The costs of intensive care. Revista Portugesa de Medicina Intensiva 2001; 10:2.

22. Hibbert CL, Corcoran MC, Dean J, Edbrooke DL, Coates EJ, Jacobs P. How much does it cost to survive in the intensive care unit. Revista Portugesa de Medicina Intensiva 2001; 10:2.

23. Hibbert CL, Edbrooke DL. Intensive Care Costs – A Reply. Anaesthesia 2002; 57:2:184. 24. Angus DC, Rubenfeld GD, Roberts MS, Curtis JR, Connors AF, Cook DJ, Lave JR, Pinsky MR,

Cohen IL, Edbrooke DL, Jacobs P, Lambrinos J, Miranda D, Hibbert C, Cook DJ, Linde-Zwirble WT, Moreni R, Tsevat J, Chalfin DB, Hlatky M, Kamlet MS, Roberts MS, Sonnenberg FA, Asch D, Morreim EH, Lave JR, Rie M. Understanding costs and cost-effectiveness in critical care – Report from the Second American Thoracic Society Workshop on Outcomes Research. American Journal of Respiratory and Critical Care Medicine 2002;165:4:540-550.

25. Jegers M, Edbrooke DL, Hibbert CL, Chalfin DB, Burchardi H. Definitions of cost assessment: an intensivist’s guide. Intensive Care Medicine 2002; 28: 1279-5.

26. Hibbert CL, Coates EJ, Edbrooke DL. SOLUTIONS SPOTLIGHT. A model to predict bed provision for critical care. International Hospital Equipment and Solutions, February/March 2002;1:30

27. Hibbert CL. A systematic review of ICU costs. Hospital, March 2002. Hospital is a bi-monthly journal produced by the European Association of Hospital Managers.

28. Hibbert CL, Morris J, Partridge S. Funding Critical Care. The Journal of the Intensive Care Society; 2003:4:1: 9-10.

29. Hibbert CL, Coates EJ. Methodological issues in studies reporting the costs of sepsis patients. Care of the Critically Ill 2004;20:6:167-176

30. Hibbert CL, Coates EJ, Brazier JE. A cost survey of 70 adult critical care units: results from a volunteer sample in England, Scotland and Northern Ireland. Care of the Critically Ill 2004;21:1:8-17.

31. Peek GJ, Clemens F, Elbourne D, Firmin R, Hardy P, Hibbert C, Killer H, Mugford M, Thalanany M, Tiruvoipati R, Truesdale A, Wilson A. CESAR : conventional ventilatory support vs. Extracorporeal membrane oxygenation for severe respiratory failure. BMC Health Services Research 2006 ; 6:163

32. Thalanany M, Mugford M, Hibbert C, Cooper N, Truesdale A, Robertson S, Tiruvoipati R, Elbourne D, Peek G, Clemens F, Hardly P, Wilson A on behalf of the CESAR Trial Group. Methods of data collection and analysis of the economic evaluation alongside a national, multicentre trial in the UK: Conventional ventilation or ECMO for severe adult respiratory failure (CSEAR). BMC Health Services Research

33. Hibbert CL, Piedra PA, McLauren KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine 2007

34. Peek GJ, Elbourne D, Mugford M, Tiruvoipati R, Wilson A, Allen E, Clemens F, Firmin R, Hardy P, Hibbert C, Jones N, Killer H, Thalanany M, Truesdale A. Randomised Controlled Trial of Conventional Ventilatory Support vs Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR) [ISRCTN47279827]. HTA Monograph

35. Peek GJ, Elbourne D, Mugford M, Tiruvoipati R, Wilson A, Allen E, Clemens F, Firmin R, Hardy P, Hibbert C, Jones N, Killer H, Thalanany M, Truesdale A. Randomised Controlled Trial of Conventional Ventilatory Support vs Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR) [ISRCTN47279827]. Lancet 2009 Oct 17; 374(9698): 1351-63.

8

36. Csomos A, Varga Sz, Bertolini G, Hibbert C, Sandor J, Capuzzo M, Guidet B on behalf of the Research Group on Health Economics of the European Society of Intensive Care Medicine. Intensive care reimbursement practices: results from the ICUFUND survey. Intensive Care Med. 2010 Oct;36(10):1759-64. doi: 10.1007/s00134-010-1911-8. Epub 2010 May 28.

38. Edbrooke DL, Hibbert CL, Wilson AJ, Mann AJ, Stevens VG. The cost of individual patient treatments in intensive care. Proceedings from the 3rd. World Conference of Surgical Efficiency & Economy. Kiel Sept 13-15 1995

39. Edbrooke, DL, Hibbert CL, Wilson AJ, Mann AJ, Stevens VG. A first evaluation into the costing of intensive care patients. 8th European Congress of Intensive Care Medicine. II Free Papers. 1995. Athens October 18-22 1995

40. Edbrooke DL, Stevens VG, Wilson AJ, Hibbert CL, Kingsley J, Mann AJ. The Provision of High Dependency Units in England - The Cost and Benefits of Development and Implementation. Intensive Care Medicine 1996;2:S3

41. S Smith, V G Stevens, A J Wilson, C Hibbert, A Mann, D L Edbrooke. Cost Implications for ICUs of the Ageing Population. Intensive Care Medicine 1996;2:S3

42. Stevens VG, Edbrooke DL, Hibbert CL, Wilson AJ. Integrated Clinical and Cost Audit in the ICU. Current Perspectives in Healthcare Computing Conference, Harrogate (7-9th March 1997) Published in Conference Proceedings

43. Edbrooke DL, Hibbert CL, Kingsley JM, Wilson AJ, Stevens VG, Smith S, Loynes RM. The costs of severe sepsis in a UK adult general intensive care unit. Intensive Care Medicine 1997;23:1:S155

44. Edbrooke DL, Hibbert CL. A Standardised Method for Costing Adult General Intensive Care Units (ICUs) in the UK. Intensive Care Medicine 1997;23:1:S155

45. Hibbert CL, Edbrooke DL. An economic model for evaluating the cost impact of new drug therapies in intensive care patients. Intensive Care Medicine 1997;23:1:S155

46. Edbrooke DL, Lindley EJ, Stevens VG, Wilson AJ, Hibbert CL. Which factors can be used to accurately predict the costs of care for intensive care patients? Intensive Care Medicine 1998;24:S58

47. Hibbert CL, Edbrooke DL. A cost analysis of ICU patients who receive low-air loss bed therapy and the additional costs involved. Intensive Care Medicine 1998;24:S58

48. Mills GH, Hibbert CL, Edbrooke DL. Can TISS be used to accurately reflect the daily costs of care for individual patients on the Intensive Care Unit? Intensive Care Medicine 1998;24:S58.

49. Hibbert CL, Edbrooke DL, Corcoran M. Is organ support the answer to costing care in the ICU? Intensive Care Medicine 1999;25:Suppl 1:S170

50. Hibbert CL, Edbrooke DL, Coates EJ. Development of a discrete event simulation model to predict bed requirements for critical care. Intensive Care Medicine 2001;

51. Coates EJ, Hibbert CL, Edbrooke DL. A cost-effectiveness study of enteral immune modulating nutrition in intensive care patients. Intensive Care Medicine 2001;

52. Bhalla S, Hibbert C, Watkins J, Beard S, Chetty M, Arellano J. To determine the cost-effectiveness of pemetrexed (PEM) compared to current standards of care in 2nd-line advanced non-small cell lung cancer (NNSCLC) from the UK National Health Service (NHS) perspective. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1, Vol, 25 No. 18S (June 20 Supplement), 2007:6540.

53. Bhalla S, Hibbert CL, Chetty M, Poole C, Miles D, Coleman R, Bruce G, Beard S, Watkins J. An evaluation of the clinical and cost-effectiveness of combination chemotherapy with gemcitabine plus paclitaxel for the treatment of Metastatic Breast Cancer (MBC) in the UK from an NHS perspective. 29th Annual San Antonio Breast Cancer Symposium. Abstract Number: 550904.

54. Edbrooke DL, Corcoran MC, Dean J, Hibbert CL, Coates E, Jacobs P. The costs of intensive care. II International Congress of Critical Care Medicine in the Internet (CIMC 2000).

9

55. Hibbert CL, Corcoran MC, Dean J, Edbrooke DL, Coates E, Jacobs P. How much does it cost to survive in the intensive care unit? II International Congress of Critical Care Medicine in the Internet (CIMC 2000).

56. Coates E, Hibbert CL. A cost-effectiveness study of enteral immune modulating nutrition in intensive care patients. III International Congress of Critical Care Medicine in the Internet (CIMC 2001).

57. Dean J, Hibbert CL, Edbrooke DL. Variation in expenditure on intensive care in university and non-university hospitals. III International Congress of Critical Care Medicine in the Internet (CIMC 2001).

58. Pike J, Liu Y, Lee A, Hibbert C, Hoskin B. Impact of walking impairment on healthcare resource utilisation in multiple sclerosis patients. ISPOR International Society for Pharmacoeconomics and Outcomes Research - 20th International Meeting (2015).

59. Vaidya S, Hibbert C, Kinter E, Boes S. Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review. Lung (in press) (2016)

Department of Health Reports 1. Deliverable 1: Evaluation of Sheffield Health-Care Costing System I - Configuration and

Deployment. A J Wilson, D L Edbrooke, C Hibbert, A Mann, V Stevens. April 1996 2. Deliverable 2: Techniques and Tools for Budget Management in the ICU. A J Wilson, C

Hibbert, V G Stevens, D L Edbrooke. April 1996 3. Deliverable 3: Evaluation of Proposed Healthcare Resource Groups (HRGs) for Intensive

Care Units (ICUs). A J Wilson, VG Stevens, D L Edbrooke, A J Mann, C L Hibbert October 1997.

4. The Provision of High Dependency Units in England - The Costs and Benefits of Development and Implementation. A Report from the Medical Economics & Research Centre, Sheffield to the Department of Health, February 1996.

5. Exploration of the potential uses of the Augmented Care Period Data Set. Medical Economics and Research Centre, Sheffield. April 1998

6. Evaluation of the number of organ systems supported (ORGSUP) as a measure of activity. Medical Economics and Research Centre, Sheffield. April 1998.

7. Problems with the collection of the Augmented Care Period Data Set. Medical Economics and Research Centre, Sheffield. April 1998

8. Edbrooke DL, Hibbert CL, Corcoran M, Bright N. A detailed analysis of the type and duration of organ support data for intensive care patients and development of appropriate cost-weightings for the Augmented Care Period Data Set. Research Report for the National Case-Mix Office, December 1998.

9. Edbrooke DL, Hibbert CL, Corcoran M. Adult Intensive Care Review: An International Perspective. Report for the NHS Executive, London. August 1999.

10. Edbrooke DL, Hibbert CL. Future provision of critical care beds in Sheffield for the next 5 years. Report for Sheffield Health, Royal Hallamshire and Northern General Hospitals. August 1999.

11. Hibbert CL, Coates E, Brazier J, Morris J. Development of Healthcare Resource Groups for adult critical care. Report for the NHS Information Authority, Jan 2004.

Conference Papers 1. Hibbert CL. Equipment utilisation in Intensive Care. National study day sponsored by the

British Association of Critical Care Nurses (BACCN), June 1996. 2. Smith S, Stevens VG, Edbrooke DL, Wilson AJ, Hibbert CL, Mann AJ. Cost implications for

intensive care of the ageing of the population. Presented at the 9th European Congress on Intensive Care Medicine, Glasgow, September 1996.

10

3. Edbrooke DL, Wilson AJ, Stevens, Hibbert CL, Mann AJ, Kingsley J. The provision of high dependency units in England - the cost and benefits of development and implementation. Presented at the 9th European Congress on Intensive Care Medicine, Glasgow, September 1996.

4. Wilson AJ, Stevens VG, Hibbert CL, Mann AJ, Edbrooke DL. Validation of HRGs for Intensive Care. Presented at The National Casemix Conference, Birmingham, October 1996.

5. Stevens VG, Edbrooke DL, Hibbert CL, Wilson AJ. Integrated clinical and cost audit in the ICU. Presented at Healthcare Computing Conference, Harrogate, March 1997.

6. Edbrooke DL, Hibbert CL. Costing methodologies in the Intensive Care Unit. University of Alberta, Edmonton. Anaesthetic and Intensive Care Division. May 1997.

7. Edbrooke DL, Hibbert CL. Costs of Intensive Care. 10th Annual Congress of the European Society of Intensive Care Medicine, Paris, September 1997.

8. Hibbert CL, Edbrooke DL. An economic model for evaluating the cost impact of new drug therapies in intensive care patients. Presented at the 10th Annual Congress of the European Society of Intensive Care Medicine, 7-10th September 1997.

9. Edbrooke DL, Hibbert CL, Kingsley JM, Wilson AJ, Stevens VG, Smith S, Loynes RM. The costs of severe sepsis in a UK adult general intensive care unit. Presented at the 10th Annual Congress of the European Society of Intensive Care Medicine, 7-10th September 1997.

10. Edbrooke DL, Hibbert CL. A Standardised Method for Costing Adult General Intensive Care Units (ICUs) in the UK. Presented at the 10th Annual Congress of the European Society of Intensive Care Medicine, 7-10th September 1997.

11. Hibbert CL, Edbrooke DL. A cost-analysis of ICU patients who receive loss-air loss bed therapy and the additional costs involved. Oral presentation at the 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm 6-9th September 1998.

12. Edbrooke DL, Lindley EJ, Stevens VG, Wilson AJ, Hibbert CL. Which factors can be used to accurately predict the costs of care for intensive care patients? Oral presentation at the 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm 6-9th September 1998.

13. Hibbert CL, Kingsley JM, Edbrooke DL. A study of nursing time and associated costs spent positioning patients in Intensive Care. Oral presentation at the 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm 6-9th September 1998.

14. Mills GH, Hibbert CL, Edbrooke DL. Can the Therapeutic Intervention Scoring System be used to accurately reflect the daily costs of care for individual patients on the Intensive Care Unit? Oral presentation at the 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm 6-9th September 1998.

15. Edbrooke DL, Hibbert CL. Cost Effectiveness in Critical Care. Intensive Care Forum: Stocktake of Adult Intensive Care, 13 February 1998. NHS Executive, Richmond House.

16. Edbrooke DL, Hibbert CL Cost and cost-effectiveness in intensive care. 10th European congress of Anaesthesiology - Frankfurt, July 1998.

17. Edbrooke DL, Hibbert CL. A European Costing Methodology. 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm, September 1998.

18. Edbrooke DL, Hibbert CL. Cost-effectiveness in Intensive Care. 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm, September 1998.

19. Edbrooke DL, Hibbert CL, Mills GH. Does it make sense to correlate TISS points against ICU costs? Austrian Society of Anaesthesiology Resuscitation and Intensive Care Medicine, Vienna October 1998.

20. Hibbert CL. Costs associated with specialised bed therapy. Oral presentation at the British Association of Critical Care Nurses, October 1998.

21. Edbrooke DL, Hibbert CL. Economical aspects of intensive care. Belgium Society of Intensive Care and Emergency Medicine, Leuven, November 1998.

11

22. Edbrooke DL, Hibbert CL. Meet the expert - How to evaluate the costs of ICU. 7th Portuguese National Congress of Intensive Care, Lisbon, November 1998.

23. Edbrooke DL, Hibbert CL. Can we afford Intensive Care? Key note address. 19th International Symposium on Intensive Care and Emergency Medicine, Belgium, March 1999.

24. Edbrooke DL, Hibbert CL. How I calculate the costs of my ICU. 19th International Symposium on Intensive Care and Emergency Medicine, Belgium, March 1999.

25. Hibbert CL. Antibiotic costing in the Intensive Care Unit, 4th Congress of the European Association of Hospital Pharmacists. Audit and Evaluation of Antibiotic Prescribing. Nice, France 17-19 March 1999 (Invited speaker).

26. Hibbert CL, Edbrooke DL. The Augmented Care Period Data Set - Can it be used for costing intensive care patients? Trent Institute for Health Services Research, 4th Annual Conference, April 1999.

27. Edbrooke DL, Hibbert CL Costing in Intensive Care. 20th International Symposium on Current Problems in Emergency and Intensive Care Medicine, Münster August 1999.

28. Hibbert CL. Costing an ICU bed. Intensive Care Nursing Symposium. The Bloomsbury Institute of Intensive Care Medicine. London 30th September 1999. (Invited speaker).

29. Edbrooke DL, Hibbert CL Costing for the uninterested. 12th Annual Congress of the European Society of Intensive Care Medicine, Berlin, October 1999.

30. Hibbert CL, Edbrooke DL, Corcoran M. Is organ support the answer to costing care in the ICU? 12th Annual Congress of the European Society of Intensive Care Medicine, Berlin, October 1999.

31. Hibbert CL. Cost Block Methodology. National Cost Block Meeting. Sheffield November 1999 (Invited speaker).

32. Hibbert CL. International Comparisons of Intensive Care. National Expert Group Meeting, London 27th January 2000.

33. Edbrooke DL, Hibbert CL. Costs, reimbursement and profits generated in a private ICU. Are there new opportunities? 6th Edition of Hospital CUF Annual Meeting, Lisbon, Portugal, June 2000.

34. Regional ICU Meeting in Belfast, sponsored by Astra Zeneca Hosted a debate on cost-effectiveness issues in intensive care. 13th June 2000.

35. Edbrooke DL, Ridley SA, Hibbert CL, Corcoran MC. Variation in expenditure between adult general ICUs in the UK. 13th Annual Congress of the European Society of Intensive Care Medicine, Rome, October 2000.

36. Hibbert CL. Modelling of critical care provision. South West Intensive Care Society. Exeter, October 2000.

37. Hibbert CL. How to audit outreach services. Critical Care Outreach Team Workshop. North Trent Critical Care Network, Swallow Hotel, Rotherham, January 2001.

38. Hibbert CL. The Augmented Care Period Data Set. North Trent Audit Training Programme, Rutland Hotel, Sheffield Feb 2001.

39. Hibbert CL. Economic implications of early feeding with enteral nutrition. Novartis Consumer Health, UK. March 2001.

40. Hibbert CL. Modelling of critical care services. Trent Regional Learning Network, Derby, 4th April 2001.

41. Hibbert CL. The National Cost Block Programme: What is involved in participation? National Meeting, Ashby de la Zouch, Leicestershire, 9th April 2001.

42. Hibbert CL. Development of the cost block method. European Programme for Resource Use in Critical Care (EPOC) Meeting. Budapest, April 2001.

43. Hibbert CL. Health economic evaluation of the adult ECMO clinical trial. National launch Meeting, London, 25th April 2001.

44. Hibbert CL. Presentation on the Critical Care National Cost Block Programme. Paediatric Intensive Care Society Directors’ Meeting, Leicester, 26th April 2001.

12

45. Hibbert CL. Cost implications of the use of IMPACTÒ in the critically ill. Novartis Consumer Health, Stockholm, 3rd May 2001.

46. Hibbert CL. Patient-level costing of adult intensive care: A systematic review of the literature. Sheffield Teaching Hospitals NHS Trust Research Forum. Cancer Research Forum, 20th June 2001.

47. Edbrooke DL, Coates E, Hibbert CL. Modelling of critical care. NPAT Meeting, 29th June 2001.

48. Hibbert CL, Edbrooke DL, Coates EJ. Development of a discrete event simulation model to predict bed requirements for critical care. 14th Annual Congress of the European Society of Intensive Care Medicine, Geneva, Oct 2001.

49. Coates EJ, Hibbert CL, Edbrooke DL. A cost-effectiveness study of enteral immune modulating nutrition in intensive care patients. 14th Annual Congress of the European Society of Intensive Care Medicine, Geneva, Oct 2001.

50 Hibbert CL. Presentation of PhD project. Graduate Conference 2001 at the School of Health and Related Research, University of Sheffield, November 2001.

51 Hibbert CL. “ICU Costs: A systematic review of costing methods”. 22nd International Symposium on Intensive Care and Emergency Medicine, Brussels Congress Center - March 19-22, 2002.

52 Hibbert CL. Costing methodology for ICU and hospital resources for the CESAR Trial, CESAR Collaborators’ Meeting, London, January 2003.

53 Hibbert CL. The Critical Care HRG Study. National Dataset Workshop in Critical Care, London, February 2003.

54 Hibbert CL. The Critical Care HRG Study. ESICM Research Group on Cost-Effectiveness Meeting, Brussels, March 2003.

55 Hibbert CL. The Critical Care HRG Study. North Manchester Clinical Network Meeting, Manchester, March 2003.

56 Hibbert CL. The Critical Care HRG Study. Mid-Trent Clinical Network Meeting, Derby, March 2003.

57 Hibbert CL. The Critical Care HRG Study. Lincoln County Hospital, March 2003. 58 Hibbert CL. The Critical Care HRG Study: A Methodology Workshop. 4th Annual Case-Mix

Conference, London, April 2003. 59 Hibbert CL. Economic Outcome Evaluation. Second Annual Cambridge Colloquium

sponsored by the International Sepsis Forum, Cambridge, Queen’s College, UK, June 28-30, 2003 (Invited Speaker)

60 Hibbert CL. Cost-efficacy vs. cost-effectiveness. Presentation to the ESICM Research Group on Health Economics, Oct 2007.

61 Hague CL. EU+ Market Access. Annual International Regulatory Affairs and SABR Affiliate & Distributor Meeting 2014. 21-23rd October 2014, Barcelona, Spain

62 Hague CL. Early Payer Advice Workshop, Biogen Idec. Moderator for Session Entitled “Overview of Historical / Established Advice Channels. Launch Event: Biogen Idec HQ, Cambridge, Boston, 20 November 2014.